Abstract
Transmissible Spongiform Encephalopathies or prion related disorders are fatal and infectious neurodegenerative diseases characterized by extensive neuronal apoptosis and accumulation of a misfolded form of the cellular prion protein (PrP), denoted PrPSc. Although the mechanism of neurodegeneration and the involvement of PrPSc is far from clear, data indicates that neuronal apoptosis might be related to activation of several signaling pathways, including proteasome dysfunction, alterations in prion maturation pathway and endoplasmic reticulum (ER) stress. In this article we describe recent studies investigating the molecular mechanism of PrPSc neurotoxicity. We propose a model in which the key step in the pathogenesis of prion disorders, independent on their etiology, is the alteration of ER-homeostasis due to drastic modifications of the physicochemical properties of PrP, leading to the activation of ER-dependent signaling pathways that controls cellular survival.
Keywords: Neurotoxicity, Spongiform Encephalopathies, endoplasmic reticulum (ER), PrPSc
Current Molecular Medicine
Title: Molecular Mechanisms of Neurotoxicity of Pathological Prion Protein
Volume: 4 Issue: 4
Author(s): Joaquin Castilla, Claudio Hetz and Claudio Soto
Affiliation:
Keywords: Neurotoxicity, Spongiform Encephalopathies, endoplasmic reticulum (ER), PrPSc
Abstract: Transmissible Spongiform Encephalopathies or prion related disorders are fatal and infectious neurodegenerative diseases characterized by extensive neuronal apoptosis and accumulation of a misfolded form of the cellular prion protein (PrP), denoted PrPSc. Although the mechanism of neurodegeneration and the involvement of PrPSc is far from clear, data indicates that neuronal apoptosis might be related to activation of several signaling pathways, including proteasome dysfunction, alterations in prion maturation pathway and endoplasmic reticulum (ER) stress. In this article we describe recent studies investigating the molecular mechanism of PrPSc neurotoxicity. We propose a model in which the key step in the pathogenesis of prion disorders, independent on their etiology, is the alteration of ER-homeostasis due to drastic modifications of the physicochemical properties of PrP, leading to the activation of ER-dependent signaling pathways that controls cellular survival.
Export Options
About this article
Cite this article as:
Castilla Joaquin, Hetz Claudio and Soto Claudio, Molecular Mechanisms of Neurotoxicity of Pathological Prion Protein, Current Molecular Medicine 2004; 4 (4) . https://dx.doi.org/10.2174/1566524043360654
DOI https://dx.doi.org/10.2174/1566524043360654 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Kv7 Channels as Targets for the Treatment of Pain
Current Pharmaceutical Design Pharmacophores for Ligand Recognition and Activation / Inactivation of the Cannabinoid Receptors
Current Pharmaceutical Design On the Physiological Role of Cytosolic 5’-nucleotidase II (cN-II): Pathological and Therapeutical Implications.
Current Medicinal Chemistry Toward The Rational Design of Cell Fate Modifiers Notch Signaling as a Target for Novel Biopharmaceuticals
Current Pharmaceutical Biotechnology Fibroblast Growth Factors, Fibroblast Growth Factor Receptors, Diseases, and Drugs
Recent Patents on Cardiovascular Drug Discovery Targeting the Endocannabinod System to Limit Myocardial and Cerebral Ischemic and Reperfusion Injury
Current Pharmaceutical Biotechnology Good, Bad, Mobile Elements: Genome’s Most Successful “Parasites” as Emerging Players in Cell and Organismal Aging
Current Pharmaceutical Design STAT Inhibition in the Treatment of Cancer: Transcription Factors as Targets for Molecular Therapy
Current Cancer Therapy Reviews Small Molecule Tyrosine Kinase Inhibitors: Potential Role in Pediatric Malignant Solid Tumors
Current Cancer Drug Targets Prodigiosins as Anti Cancer Agents: Living Upto Their Name
Current Pharmaceutical Design Selection and Characterization of Human Anti-MAGE-A1 scFv and Immunotoxin
Anti-Cancer Agents in Medicinal Chemistry Nanoparticle Based Delivery of Protease Inhibitors to Cancer Cells
Current Medicinal Chemistry Synthesized 2-Trifluoromethylquinazolines and Quinazolinones Protect BV2 and N2a Cells against LPS- and H<sub>2</sub>O<sub>2</sub>-induced Cytotoxicity
Medicinal Chemistry <i>Lepidium meyenii</i> Supplemented Diet Modulates Neurobehavioral and Biochemical Parameters in Mice Fed High-Fat High-Sugar Diet
Endocrine, Metabolic & Immune Disorders - Drug Targets NAMPT in Regulated NAD Biosynthesis and its Pivotal Role in Human Metabolism
Current Medicinal Chemistry Diagnostic and Therapeutic Uses of Nanomaterials in the Brain
Current Medicinal Chemistry The Problem of Amino Acid Complementarity and Antisense Peptides
Current Protein & Peptide Science <i>Larrea tridentata</i> and its Biological Activities
Current Topics in Medicinal Chemistry The Hydroxamic Acids as Potential Anticancer and Neuroprotective Agents
Current Medicinal Chemistry Neurotrophin Propeptides: Biological Functions and Molecular Mechanisms
Current Protein & Peptide Science